{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=4",
    "query": {
      "condition": "Minimal Residual Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 186,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Minimal+Residual+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T20:04:49.732Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06993675",
      "title": "Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Teclistamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noffar Bar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-21",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Rochester, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06993675"
    },
    {
      "nct_id": "NCT02458014",
      "title": "Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Complete Remission",
        "B Acute Lymphoblastic Leukemia",
        "Minimal Residual Disease",
        "Philadelphia Chromosome Positive"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TKI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2015-09-14",
      "completion_date": "2025-09-16",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02458014"
    },
    {
      "nct_id": "NCT02988466",
      "title": "Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Haplo HCT ≥55 years old",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GVHD Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Haplo HCT ≥55 and < 65 years old",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Haplo HCT ≥65 and ≤75 years old",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 78,
      "start_date": "2017-01-24",
      "completion_date": "2025-03-24",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02988466"
    },
    {
      "nct_id": "NCT02159495",
      "title": "Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia in Remission",
        "Acute Biphenotypic Leukemia",
        "Early Relapse of Acute Myeloid Leukemia",
        "Late Relapse of Acute Myeloid Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Acute Myeloid Leukemia",
        "Adult Acute Lymphoblastic Leukemia",
        "Interleukin-3 Receptor Subunit Alpha Positive",
        "Minimal Residual Disease",
        "Refractory Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-12-15",
      "completion_date": "2027-07-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159495"
    },
    {
      "nct_id": "NCT05036109",
      "title": "DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DRUG"
        },
        {
          "name": "Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Physical Activity",
          "type": "OTHER"
        },
        {
          "name": "Behavioral Support Counseling Sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-10-12",
      "completion_date": "2026-02-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05036109"
    },
    {
      "nct_id": "NCT07517705",
      "title": "MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Low-Dose Radiation Therapy (LDRT)",
          "type": "RADIATION"
        },
        {
          "name": "Standard Frontline Chemoimmunotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-06-12",
      "completion_date": "2032-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517705"
    },
    {
      "nct_id": "NCT03441061",
      "title": "Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "B Acute Lymphoblastic Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-02-15",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03441061"
    },
    {
      "nct_id": "NCT04827745",
      "title": "Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mixed Phenotype Acute Leukemia (MPAL)",
        "Measurable Residual Disease (MRD)"
      ],
      "interventions": [
        {
          "name": "BLINCYTO (Blinatumomab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-06-11",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827745"
    },
    {
      "nct_id": "NCT01158885",
      "title": "Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Minimal Residual Disease",
        "Leukemia, Lymphoblastic, Acute",
        "Leukemia, Myelogenous, Acute"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine intravenous",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Intrathecal (IT) Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 2,
      "start_date": "2010-08",
      "completion_date": "2012-10-24",
      "has_results": true,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Seattle, Washington",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158885"
    },
    {
      "nct_id": "NCT02370888",
      "title": "Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2016-05-16",
      "completion_date": "2019-05-31",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-10-06T20:04:49.732Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02370888"
    }
  ]
}